Below are the 2016 stem cell predictions I produced last year and their status now color-coded near year’ s end. Green is right, orange is mixed handbag, and red is flat out wrong.
General, I did better than most past years with only getting entirely blown it on four.
Stay tuned later this week for my 2017 predictions, which looks to be a dramatic year in the field of come cells and regenerative medicine.
The Score Card on 2016 Predictions
- Another stem cell biotech order by pharma (recall Ocata (now finally sold in order to Astellas) & CDI in 2015). Quality: Some acquisitions, but not large news.
- Charging patients with regard to clinical trial participation, particularly in Japan due to the brand new policy and here in the US related to predatory clinics remains the hot topic. Grade: Correct.
- Stem cell clinics and doping in sports flares up more. Quality: not really the two together.
- Organoids continue to excite. Grade: Right.
- Bioheart and some other little stem cell companies struggle. Grade: Correct.
- Stem cell shares overall have a bad year. Grade: Unfortunately, generally correct.
- Come cell clinics ever more aggressively use celeb clients just for PR and marketing. Why? It is powerful, effective, plus essentially free advertising. Grade: Right.
- More news on human-animal chimeras. Grade: Correct.
- FDA continues its slow-go approach to activity on stem cell clinics/unapproved stem cell products. Grade: Sadly correct.
- Pressure from industry and some academics on FOOD AND DRUG ADMINISTRATION to not regulate adipose products as drugs and/or not to enforce some other draft guidances including at the public listening to on the draft guidances. Grade: Appropriate.
- FDA receives increasing open public criticism for “ slowness” on approving new come cell therapies including from beyond the stem cellular clinic industry. Grade: Correct.
- One or more lawsuits against an originate cell clinic. Grade: Correct in the big way. E. g. versus U. S. Come Cell, Lung Institute, and Stemgenex.
- A new stem cell scandal pops up related to distribution issues. Grade: Correct. You just need to go visit Retraction Watch (e. g. the The country of spain mess), For Better Science, or PubPeer, and then furthermore see the continuing Macchiarini debacle in particular.
- Some hiccups on mitochondrial transfer/3-person IVF in the united kingdom or China. Grade: Correct. Unhealthy mitochondrial carry-over and mito-nuclear cross-talk issues have sprang up and deserve serious attention. Remarkably, nevertheless UK folks are going forward with it in people anyway.
- The trend last year of increasingly blurry lines between legit research entities such as universities plus dubious stem cell enterprises continues. This is worrisome. Grade: Correct. For example, see Rasko paper .
- Stem cell-derived human germ cells stay in the head lines. This has exciting potential for providing new windows into individual development and tackling infertility, but also raises thorny problems such as human genetic modification. Grade: Correct.
- ViaCyte has some large news. Grade: Not yet…
- High-profile developments on veterinary use of stem cells. Grade: Correct.
- Animal cloning, particularly in China, continues to proliferate. Grade: Correct.
- More rumblings on possible human reproductive cloning tries. Grade: Some here and there, although not much. See this piece on cloning focusing on 20th Anniversary of Dolly.